MedTrace Logo

Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)

NCT05522569 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to use an intravenous infusion of allogeneic human mesenchymal stem cells (Allo-hMSCs) to treat an acute ischemic stroke condition.

Conditions

  • Acute Ischemic Stroke
  • Mesenchymal Stem Cells
  • Stroke, Acute
  • Stroke/Brain Attack
  • Stroke, Ischemic

Interventions

DRUG

Allogeneic human mesenchymal stem cells (Allo-hMSCs)

Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Dileep Yavagal, MD · University of Miami

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05522569 on ClinicalTrials.gov